Glaxosmithkline Asia Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 5.50 Cr
as on 16-11-2024
- Company Age 29 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 15.62%
(FY 2023)
- Profit -19.86%
(FY 2023)
- Ebitda -7.51%
(FY 2023)
- Net Worth -16.22%
(FY 2023)
- Total Assets -6.51%
(FY 2023)
About Glaxosmithkline Asia
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 5.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ramesh Gupta, Anurita Chopra, Kanika Wadhwa, and One other member serve as directors at the Company.
- CIN/LLPIN
U99999PB1995PTC028476
- Company No.
028476
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Oct 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Patiala, Punjab, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Glaxosmithkline Asia?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Gupta  | Director | 01-Oct-2008 | Current |
| Nitin Mathur | Whole-Time Director | 30-Jan-2021 | Current |
| Anurita Chopra | Whole-Time Director | 05-Sep-2016 | Current |
| Kanika Wadhwa | Whole-Time Director | 12-Mar-2019 | Current |
Financial Performance and Corporate Structure Insights of Glaxosmithkline Asia.
Glaxosmithkline Asia Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.62% increase. The company also saw a substantial fall in profitability, with a 19.86% decrease in profit. The company's net worth observed a substantial decline by a decrease of 16.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glaxosmithkline Asia?
In 2023, Glaxosmithkline Asia had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Glaxosmithkline Asia?
Glaxosmithkline Asia has a workforce of 789 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glaxosmithkline Asia, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glaxosmithkline Asia's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
